7Baggers

Agios Pharmaceuticals, Inc
(NASDAQ:AGIO) 

AGIO stock logo

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refracto...

Founded: 2008
Full Time Employees: 536
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 
                                                        
      revenues:
    		                                                    
      product revenue
    		20,746,000 19,967,000 12,880,000 12,455,000 8,726,000 10,730,000 8,964,000 8,615,000 8,189,000 7,103,000 7,399,000 6,712,000 5,609,000 4,310,000 3,516,000 3,082,000 832,000     39,118,000 31,716,000 27,581,000 22,674,000 19,564,000 17,422,000 13,727,000 9,138,000 9,376,000 4,465,000                      
      total revenue
    		20,746,000 19,967,000 12,880,000 12,455,000 8,726,000 10,730,000 8,964,000 8,615,000 8,189,000 7,103,000 7,399,000 6,712,000 5,609,000 4,310,000 3,516,000 5,582,000 832,000     44,045,000 34,706,000 37,347,000 87,098,000 35,440,000 26,024,000 26,221,000 30,227,000 30,013,000 15,198,000 40,414,000 8,762,000 9,799,000 11,358,000               6,744,000 6,268,000 6,268,000 
      yoy
    		137.75% 86.09% 43.69% 44.57% 6.56% 51.06% 21.15% 28.35% 46.00% 64.80% 110.44% 20.24% 574.16%         24.28% 33.36% 42.43% 188.15% 18.08% 71.23% -35.12% 244.98% 206.29% 33.81%                      
      qoq
    		3.90% 55.02% 3.41% 42.73% -18.68% 19.70% 4.05% 5.20% 15.29% -4.00% 10.24% 19.66% 30.14% 22.58% -37.01% 570.91%      26.91% -7.07% -57.12% 145.76% 36.18% -0.75% -13.25% 0.71% 97.48% -62.39% 361.24% -10.58% -13.73%                7.59% 0.00%  
      operating expenses:
    		                                                    
      cost of sales
    		1,319,000 1,879,000 1,679,000 1,702,000 1,085,000 1,260,000 783,000 1,495,000 627,000 586,000 633,000 1,108,000 554,000 413,000 517,000 435,000 339,000     959,000 638,000 675,000 533,000 287,000 393,000 303,000 334,000 702,000 695,000                      
      research and development
    		81,148,000 88,056,000 86,796,000 91,940,000 72,743,000 82,810,000 72,455,000 77,401,000 68,620,000 77,489,000 81,841,000 68,895,000 67,301,000 70,298,000 64,966,000 74,523,000 70,123,000 73,299,000 64,000,000 62,007,000 57,667,000 95,742,000 89,555,000 90,917,000 91,256,000 106,248,000 101,672,000 107,389,000 95,585,000 93,809,000 82,561,000 86,730,000 78,224,000 77,216,000 72,917,000 79,816,000 62,732,000 64,678,000 60,643,000 50,804,000 44,038,000 36,933,000 36,028,000 36,423,000 32,443,000 34,862,000 25,526,000 22,576,000 17,407,000 15,279,000 14,803,000 12,958,000 
      selling, general and administrative
    		48,304,000 51,610,000 41,274,000 45,869,000 41,527,000 51,697,000 38,537,000 35,536,000 31,014,000 35,305,000 25,822,000 30,409,000 28,367,000 32,771,000 29,123,000 28,264,000 31,515,000 31,528,000 27,152,000 29,215,000 33,550,000 39,778,000 34,840,000 35,951,000 38,501,000 34,834,000 33,019,000 32,390,000 31,791,000                        
      total operating expenses
    		130,771,000 141,545,000 129,749,000 139,511,000 115,355,000 135,767,000 111,775,000 114,432,000 100,261,000 113,380,000 108,296,000 100,412,000 96,222,000 103,482,000 94,606,000                 113,363,000 102,774,000 99,929,000 90,375,000 95,946,000 77,555,000 80,057,000 72,497,000 63,448,000 54,875,000 47,116,000 45,955,000 45,352,000 39,397,000 41,363,000 30,692,000 26,741,000 20,695,000 18,986,000 17,337,000 14,794,000 
      income from operations
    		-110,025,000 -121,578,000 -116,869,000 -127,056,000 -106,629,000 -125,037,000 -102,811,000 -105,817,000 -92,072,000 -106,277,000 -100,897,000 -93,700,000 -90,613,000 -99,172,000 -91,090,000 -97,640,000 -101,145,000 -104,827,000 -91,152,000 -91,222,000 -91,217,000 -92,434,000 -90,327,000 -90,196,000 -43,192,000 -105,929,000 -109,060,000 -113,861,000 -97,483,000 -96,356,000 -99,162,000 -72,949,000 -94,012,000 -90,130,000 -79,017,000 -84,600,000 -67,047,000 -57,409,000 -63,512,000 -56,470,000 -23,594,000 -40,898,000 -40,475,000 -32,133,000 -5,195,000 -26,727,000 3,208,000 -18,330,000 -12,284,000 -12,242,000 -11,069,000 -8,526,000 
      yoy
    		3.18% -2.77% 13.67% 20.07% 15.81% 17.65% 1.90% 12.93% 1.61% 7.16% 10.77% -4.04% -10.41% -5.39% -0.07% 7.04% 10.88% 13.41% 0.91% 1.14% 111.19% -12.74% -17.18% -20.78% -55.69% 9.94% 9.98% 56.08% 3.69% 6.91% 25.49% -13.77% 40.22% 57.00% 24.41% 49.81% 184.17% 40.37% 56.92% 75.74% 354.17% 53.02% -1361.69% 75.30% -57.71% 118.32% -128.98% 114.99%     
      qoq
    		-9.50% 4.03% -8.02% 19.16% -14.72% 21.62% -2.84% 14.93% -13.37% 5.33% 7.68% 3.41% -8.63% 8.87% -6.71% -3.47% -3.51% 15.00% -0.08% 0.01% -1.32% 2.33% 0.15% 108.83% -59.23% -2.87% -4.22% 16.80% 1.17% -2.83% 35.93% -22.40% 4.31% 14.06% -6.60% 26.18% 16.79% -9.61% 12.47% 139.34% -42.31% 1.05% 25.96% 518.54% -80.56% -933.14% -117.50% 49.22% 0.34% 10.60% 29.83%  
      operating margin %
    		-530.34% -608.89% -907.37% -1020.12% -1221.97% -1165.30% -1146.93% -1228.29% -1124.34% -1496.23% -1363.66% -1396.01% -1615.49% -2300.97% -2590.73% -1749.19% -12156.85% -Infinity% -Infinity% -Infinity% -Infinity% -209.86% -260.26% -241.51% -49.59% -298.90% -419.07% -434.24% -322.50% -321.05% -652.47% -180.50% -1072.95% -919.79% -695.69% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -181.52% -176.60% -136.02% 
      interest income
    		10,795,000 12,410,000 13,369,000 14,513,000 16,087,000 18,015,000 13,059,000 8,120,000 8,889,000 8,624,000 8,375,000 8,254,000 8,091,000 6,488,000 3,818,000 1,793,000 694,000 332,000 256,000 -92,000 340,000 791,000 1,115,000 1,769,000 2,936,000 3,579,000 2,887,000 3,990,000 4,405,000 4,562,000 4,498,000 4,204,000 3,187,000 1,845,000 1,880,000 1,518,000 881,000 923,000 678,000 517,000 396,000 276,000 218,000 236,000 238,000 85,000 48,000 34,000 36,000 29,000 13,000 5,000 
      other income
    		119,000 113,000 67,000 523,000 1,253,000 1,623,000 1,651,000 1,579,000 1,634,000 1,713,000 1,198,000 1,640,000 1,504,000 1,357,000 1,082,000 1,337,000 2,973,000 3,268,000 4,641,000 6,524,000                                 
      net income
    		-99,111,000 -108,039,000 -103,433,000 -112,020,000 -89,289,000 -96,523,000 947,915,000 -96,118,000 -81,549,000 -95,940,000 -91,324,000 -83,806,000 -81,018,000 36,526,000 -81,747,000 -91,806,000 -94,774,000 -94,627,000 -88,766,000 -86,217,000 1,874,325,000 -97,657,000 -98,979,000 -90,478,000 -40,256,000 -102,350,000 -106,173,000 -109,871,000 -93,078,000 -91,794,000 -94,664,000 -68,745,000 -90,825,000 -88,285,000 -77,137,000 -83,082,000 -66,166,000 -56,486,000 -62,834,000 -55,953,000 -23,198,000 -40,622,000 -40,257,000 -31,897,000 -4,957,000 -26,664,000 3,704,000 -18,296,000 -12,248,000 -12,382,000 -11,177,000 -8,620,000 
      yoy
    		11.00% 11.93% -110.91% 16.54% 9.49% 0.61% -1137.97% 14.69% 0.66% -362.66% 11.72% -8.71% -14.51% -138.60% -7.91% 6.48% -105.06% -3.10% -10.32% -4.71% -4756.01% -4.59% -6.78% -17.65% -56.75% 11.50% 12.16% 59.82% 2.48% 3.97% 22.72% -17.26% 37.27% 56.30% 22.76% 48.49% 185.22% 39.05% 56.08% 75.42% 367.98% 52.35% -1186.85% 74.34% -59.53% 115.34% -133.14% 112.25%     
      qoq
    		-8.26% 4.45% -7.67% 25.46% -7.49% -110.18% -1086.20% 17.87% -15.00% 5.05% 8.97% 3.44% -321.81% -144.68% -10.96% -3.13% 0.16% 6.60% 2.96% -104.60% -2019.29% -1.34% 9.40% 124.76% -60.67% -3.60% -3.37% 18.04% 1.40% -3.03% 37.70% -24.31% 2.88% 14.45% -7.16% 25.57% 17.14% -10.10% 12.30% 141.20% -42.89% 0.91% 26.21% 543.47% -81.41% -819.87% -120.24% 49.38% -1.08% 10.78% 29.66%  
      net income margin %
    		-477.74% -541.09% -803.05% -899.40% -1023.25% -899.56% 10574.69% -1115.71% -995.84% -1350.70% -1234.27% -1248.60% -1444.43% 847.47% -2325.00% -1644.68% -11391.11% -Infinity% -Infinity% -Infinity% Infinity% -221.72% -285.19% -242.26% -46.22% -288.80% -407.98% -419.02% -307.93% -305.85% -622.87% -170.10% -1036.58% -900.96% -679.14% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -183.60% -178.32% -137.52% 
      net income per share
    		-1.69 -1.85 -1.78 -1.93 -1.55 -1.72 16.65 -1.69 -1.45 -1.72 -1.64 -1.51 -1.47 0.67 -1.49 -1.68 -1.74 -0.64 -1.56 -1.41 26.95 -1.41 -1.43 -1.31 -0.59 -1.59 -1.81 -1.87 -1.59 -1.58 -1.63 -1.19 -1.63 -1.81 -1.59 -1.78 -1.56 -1.35 -1.63 -1.47 -0.61 -1.09 -1.07 -0.85 -0.13 -0.78 0.11 -0.54 -0.39 -0.57 -0.47 -2.8 
      weighted-average number of common shares used in computing net loss per share – basic and diluted
    		58,782,241   57,932,576 57,459,195   56,802,546 56,383,475  55,803,663 55,604,330 55,265,390         68,997,879 69,144,061 68,958,091 68,608,279 59,994,539 58,803,534 58,722,244 58,453,918 57,418,300 58,033,386 57,721,786 55,694,603 46,587,631 48,459,424 46,745,760 42,280,525                
      gain on sale of contingent payments
    		      889,136,000                                              
      milestone payment from gain on sale of oncology business
    		      200,000,000                                              
      net income before taxes
    		 -109,055,000 -103,433,000   -105,399,000 1,001,035,000                                              
      income tax expense
    		     -8,876,000 53,120,000                                              
      weighted-average number of common shares used in computing net income per share – basic
    		 57,972,004 58,139,277   56,807,415 56,939,403                                              
      weighted-average number of common shares used in computing net income per share – diluted
    		 57,972,004 58,139,277   57,889,255 58,432,796                                              
      milestone revenue
    		               2,500,000                                     
      royalty income from gain on sale of oncology business
    		              4,443,000 2,704,000 2,704,000                                    
      net income from continuing operations
    		             36,526,000 -81,747,000 -91,806,000 -94,774,000 -98,584,000 -84,259,000 -82,790,000 -90,877,000                                
      net income from discontinued operations, net of tax
    		                 3,957,000 -4,507,000 -3,427,000 1,965,202,000                                
      net loss from continuing operations per share - basic and diluted
    		             0.67 -1.49 -1.68 -1.74 -1.77 -1.48 -1.36 -1.31                                
      net income from discontinued operations per share - basic and diluted
    		                 1.14 -0.08 -0.06 28.26                                
      weighted-average number of common shares used in computing net loss per share from continuing operations, net income from discontinued operations and net income per share – basic and diluted
    		              54,844,579 54,799,680 54,555,467                                    
      cost and expenses:
    		                                                    
      total cost and expenses
    		               103,222,000 101,977,000 104,827,000 91,152,000 91,222,000 91,217,000 136,479,000 125,033,000 127,543,000 130,290,000 141,369,000 135,084,000 140,082,000 127,710,000 126,369,000 114,360,000                      
      gain on sale of oncology business
    		                 2,643,000 1,996,000 2,000,000                                 
      weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net income per share – basic and diluted
    		         55,651,487    54,789,435    60,447,346 57,048,175 61,066,977                                 
      weighted-average number of common shares used in computing net income per share from continuing operations and discontinued operations and net income per share – basic and diluted
    		                    69,543,510                                
      collaboration revenue – related party
    		                     1,236,000 1,206,000 5,735,000 60,097,000 6,843,000 5,516,000 8,979,000 17,919,000 18,183,000 8,732,000 26,401,000 7,345,000 8,577,000 10,643,000 11,346,000 10,508,000 22,648,000 8,985,000 6,978,000 31,281,000 6,218,000 5,480,000 13,219,000 34,202,000   8,411,000     
      collaboration revenue – other
    		                     785,000 1,101,000 692,000 993,000 6,060,000 420,000 812,000 970,000 230,000  12,440,000                     
      royalty revenue – related party
    		                     2,906,000 683,000 3,339,000 3,334,000 2,973,000 2,666,000 2,703,000 2,200,000 2,224,000 2,001,000 1,573,000 1,417,000 1,222,000 715,000                  
      non-cash interest expense for the sale of future revenue
    		                     -6,014,000 -9,767,000 -2,051,000                             
      sales, general and administrative
    		                             20,571,750 31,104,000                      
      general and administrative
    		                               26,633,000 24,550,000 22,713,000 17,458,000 16,130,000 14,823,000 15,379,000 11,854,000 12,644,000 10,837,000 10,183,000 9,927,000 8,929,000 6,954,000 6,501,000 5,166,000 4,165,000 3,288,000 3,707,000 2,534,000 1,836,000 
      weighted-average number of common shares used in net loss per share – basic and diluted
    		                                     39,126,400 38,548,153 37,956,383 37,864,084   37,329,220 37,214,747        
      income before benefit for income taxes
    		                                         -19,277,500 -40,257,000          
      benefit for income taxes
    		                                                    
      weighted-average number of common shares used in net income per share – basic
    		                                          37,507,298          
      weighted-average number of common shares used in net income per share – diluted
    		                                          37,507,298          
      gross collaboration revenue – related party
    		                                             12,680,500 33,900,000      
      income before provision for income taxes
    		                                             -26,642,000 3,256,000 -18,296,000 -12,248,000 -12,213,000 -11,056,000 -8,521,000 
      provision for income taxes
    		                                             22,000 -448,000   169,000 121,000 99,000 
      cumulative preferred stock dividends
    		                                                 -8,324,000 567,000 -1,798,000 
      net income applicable to common stockholders
    		                                             -6,710,000 3,704,000      
      weighted-average number of common shares used in net income per share applicable to common stockholders – basic
    		                                              34,495,076      
      weighted-average number of common shares used in net income per share applicable to common stockholders – diluted
    		                                              36,592,683      
      net loss applicable to common stockholders
    		                                               -18,296,000 -12,248,000 -20,706,000 -10,610,000 -10,418,000 
      weighted-average number of common shares used in net loss per share applicable to common stockholders – basic and diluted
    		                                         37,429,262    33,667,024  33,602,472 31,394,563 15,415,373 22,744,486 3,722,963 
      collaboration revenue—related party
    		                                                8,411,000    
      collaboration revenue
    		                                                 6,744,000 6,268,000 6,268,000 
      grant revenue
    		                                                    
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 
                                                          
        assets
      		                                                    
        current assets:
      		                                                    
        cash and cash equivalents
      		113,600,000 89,130,000 92,710,000 80,871,000 78,964,000 76,247,000 253,730,000 84,518,000 118,764,000 88,205,000 64,333,000 84,753,000 104,139,000 139,259,000 122,449,000 88,543,000 80,026,000 203,126,000 400,224,000 969,124,000 1,888,025,000 127,436,000 104,855,000 295,858,000 89,093,000 80,931,000 81,709,000 83,580,000 103,443,000 70,502,000 156,478,000 210,323,000 364,469,000 102,724,000 132,741,000 138,717,000 200,278,000 160,754,000 285,502,000 234,048,000 39,035,000 71,764,000 80,048,000 72,533,000 35,256,000 14,031,000 70,049,000 108,247,000 32,837,000 71,560,000 106,011,000 77,481,000 
        marketable securities
      		623,438,000 765,295,000 860,150,000 858,066,000 814,411,000 817,463,000 751,027,000 485,374,000 479,227,000 688,723,000 583,155,000 617,813,000 635,062,000 643,860,000 605,231,000 730,766,000 843,503,000 816,892,000 865,833,000 703,864,000 447,578,000 445,493,000 500,684,000 494,270,000 439,528,000 483,946,000 370,188,000 411,810,000 421,114,000 514,800,000 513,414,000 506,582,000 417,981,000 321,212,000 375,187,000 447,325,000 279,480,000 380,560,000 293,595,000 231,321,000 273,859,000 245,238,000 272,317,000 297,261,000 309,450,000 328,034,000 149,921,000 130,233,000 129,432,000 95,209,000 88,945,000 21,794,000 
        accounts receivable
      		16,132,000 10,577,000 5,029,000 4,986,000 3,344,000 4,109,000 3,118,000 3,762,000 3,453,000 2,810,000 1,176,000 2,251,000 1,778,000 2,206,000 1,818,000 1,598,000 540,000     21,328,000 18,989,000 12,023,000 11,813,000 8,952,000 7,106,000 7,147,000 4,355,000 5,076,000 2,631,000                      
        inventory
      		35,087,000 32,920,000 32,034,000 30,848,000 29,605,000 27,616,000 26,429,000 23,937,000 23,070,000 19,076,000 17,274,000 15,671,000 11,374,000 8,492,000 5,176,000 4,060,000 2,485,000     14,698,000 11,371,000 11,231,000 9,778,000 7,331,000 5,849,000 4,659,000 2,328,000 869,000 863,000                      
        prepaid expenses and other current assets
      		46,586,000 44,130,000 43,186,000 44,693,000 42,292,000 40,165,000 39,885,000 34,536,000 39,113,000 35,021,000 38,414,000 36,751,000 39,303,000 38,955,000 46,487,000 42,336,000 43,226,000 39,835,000 32,238,000 21,443,000 19,511,000 23,651,000 28,861,000 26,959,000 29,152,000 24,177,000 19,985,000 19,063,000 19,696,000 17,167,000 16,458,000 15,538,000 15,614,000 17,486,000 15,316,000 13,018,000 12,391,000 10,264,000 10,277,000 8,923,000 9,190,000 8,728,000 7,225,000 4,602,000 5,512,000 4,814,000 4,990,000 2,842,000 3,033,000 2,502,000 2,616,000 2,011,000 
        total current assets
      		834,843,000 942,052,000 1,033,109,000 1,019,464,000 968,616,000 965,600,000 1,074,189,000 632,127,000 663,627,000 833,835,000 704,352,000 757,239,000 791,656,000 832,772,000 784,935,000 870,007,000 975,145,000 1,064,231,000 1,305,285,000 1,702,562,000 2,355,114,000 636,677,000 669,086,000 846,355,000 587,274,000 611,704,000 490,144,000 533,705,000 557,095,000 613,780,000 695,542,000 753,782,000 802,993,000 445,261,000 528,307,000 604,681,000 506,866,000 559,892,000 600,943,000 484,159,000 329,469,000 337,329,000 371,660,000 390,152,000 364,141,000 359,546,000 247,560,000 245,163,000 172,417,000 169,747,000 198,818,000 102,533,000 
        operating lease assets
      		27,196,000 30,454,000 33,650,000 36,785,000 39,861,000 42,879,000 45,841,000 48,750,000 51,606,000 54,409,000 57,162,000 59,866,000 62,521,000 65,129,000 67,692,000 70,214,000 72,688,000 75,124,000 77,532,000 79,901,000 82,244,000 84,661,000 86,952,000 89,208,000 91,440,000 93,643,000 95,833,000 98,500,000 57,768,000                        
        property and equipment
      		10,566,000 10,775,000 10,675,000 10,579,000 11,067,000 11,675,000 11,819,000 12,726,000 14,119,000 15,382,000 16,785,000 19,634,000 21,438,000 22,987,000 25,438,000 27,382,000 29,195,000 28,923,000 25,342,000 27,056,000 28,976,000 32,291,000 33,495,000 33,925,000 33,840,000 31,472,000 24,060,000 23,016,000 23,974,000 24,320,000 24,613,000 24,134,000 23,732,000 24,431,000 24,019,000 24,771,000 24,139,000 25,337,000 26,261,000 25,134,000 22,950,000 23,220,000 21,127,000 19,328,000 14,297,000 6,386,000 3,677,000 3,210,000 3,452,000 3,758,000 3,551,000 3,818,000 
        other non-current assets
      		3,931,000 3,931,000 3,930,000 3,942,000 4,721,000 4,724,000 4,056,000 4,056,000 4,056,000 4,057,000 4,057,000 4,057,000 3,956,000 3,956,000 3,903,000 3,955,000 2,900,000 2,900,000 2,900,000 2,900,000  1,125,000       60,000 238,000 416,000 595,000 1,104,000 891,000 1,070,000 1,249,000 2,888,000 1,615,000 1,339,000              
        total assets
      		1,184,990,000 1,297,225,000 1,385,705,000 1,471,237,000 1,555,518,000 1,663,199,000 1,791,794,000 773,063,000 849,709,000 937,118,000 1,007,258,000 1,085,153,000 1,151,298,000 1,238,718,000 1,180,320,000 1,252,467,000 1,335,859,000 1,437,736,000 1,541,498,000 1,874,603,000 2,488,434,000 852,952,000 908,449,000 976,141,000 799,738,000 890,741,000 698,616,000 783,870,000 822,131,000 858,457,000 929,079,000 998,235,000 1,040,126,000 614,397,000 687,200,000 760,600,000 557,316,000 619,094,000 672,042,000 557,601,000 396,117,000 420,065,000 449,086,000 474,383,000 474,336,000 491,904,000 269,608,000 272,030,000 181,912,000 201,205,000 219,069,000 111,252,000 
        liabilities and stockholders’ equity
      		                                                    
        current liabilities:
      		                                                    
        accounts payable
      		13,747,000 18,355,000 19,553,000 17,532,000 13,726,000 16,643,000 17,143,000 10,035,000 11,155,000 9,780,000 13,271,000 11,626,000 8,662,000 18,616,000 10,415,000 7,790,000 11,551,000 16,700,000 10,308,000 7,654,000 51,224,000 26,844,000 12,853,000 15,461,000 18,707,000 21,896,000 21,511,000 15,435,000 12,413,000 17,880,000 16,616,000 17,320,000 17,932,000 22,767,000 17,899,000 23,409,000 16,152,000 17,106,000 15,424,000 18,448,000 13,746,000 14,748,000 8,971,000 8,914,000 12,640,000 11,067,000 6,225,000 5,388,000 4,411,000 3,678,000 2,140,000 3,038,000 
        accrued expenses
      		26,293,000 45,459,000 37,217,000 35,289,000 20,761,000 46,861,000 33,307,000 36,742,000 25,129,000 43,167,000 30,490,000 29,189,000 22,459,000 30,350,000 29,756,000 28,383,000 19,747,000 31,967,000 29,234,000 36,054,000 23,601,000 60,140,000 49,724,000 41,911,000 39,631,000 53,142,000 46,750,000 49,218,000 37,199,000 42,147,000 25,303,000 25,793,000 17,005,000 34,031,000 30,760,000 29,641,000 25,114,000 32,002,000 22,808,000 14,414,000 12,247,000 15,996,000 15,985,000 11,584,000 15,604,000 14,020,000 10,004,000 5,456,000 3,841,000 6,586,000 4,764,000 3,586,000 
        operating lease liabilities
      		18,805,000 18,392,000 17,987,000 17,589,000 17,196,000 16,781,000 16,319,000 15,860,000 15,407,000 15,008,000 14,664,000 14,326,000 13,992,000 13,663,000 13,342,000 12,056,000 11,744,000 10,828,000 9,883,000 8,932,000 7,988,000 7,093,000 6,881,000 6,672,000 6,466,000 6,642,000 7,298,000 6,397,000 9,128,000                        
        total current liabilities
      		58,845,000 82,206,000 74,757,000 70,410,000 52,366,000 81,156,000 119,451,000 62,637,000 51,691,000 67,955,000 58,425,000 55,141,000 45,113,000 62,629,000 53,596,000 48,396,000 45,792,000 59,826,000 57,896,000 60,649,000 96,504,000 94,394,000 69,771,000 64,353,000 69,858,000 92,886,000 92,432,000 89,504,000 80,907,000 93,503,000 84,746,000 84,870,000 74,699,000 94,941,000 88,112,000 93,648,000 82,429,000 88,433,000 78,003,000 67,264,000 45,055,000 52,888,000 49,756,000 45,198,000 36,379,000 61,089,000 35,084,000 44,638,000 34,081,000 36,930,000 37,377,000 36,979,000 
        operating lease liabilities, net of current portion
      		16,940,000 21,815,000 26,528,000 31,171,000 35,744,000 40,207,000 44,515,000 48,760,000 52,940,000 56,988,000 60,834,000 64,620,000 68,346,000 71,996,000 75,499,000 78,946,000 82,338,000 85,659,000 88,840,000 91,971,000 95,052,000 97,458,000 99,693,000 101,874,000 104,010,000 106,074,000 108,096,000 110,073,000 66,006,000                        
        other non-current liabilities
      		90,000 90,000 90,000 101,000 880,000 880,000 1,156,000 1,156,000 1,156,000 1,156,000 1,156,000 1,156,000 1,313,000 3,279,000 1,055,000 1,055,000                                2,000 3,000  262,000  
        total liabilities
      		75,875,000 104,111,000 101,375,000 101,682,000 88,990,000 122,243,000 165,122,000 112,553,000 105,787,000 126,099,000 120,415,000 120,917,000 114,772,000 137,904,000 130,150,000 128,397,000 128,406,000 145,761,000 146,736,000 152,787,000 191,804,000 453,452,000 427,997,000 417,676,000 174,439,000 250,213,000 250,325,000 251,193,000 201,874,000 170,920,000 168,866,000 175,093,000 174,532,000 238,894,000 237,394,000 251,608,000                 
        stockholders’ equity:
      		                                                    
        preferred stock, 0.001 par value...
      		                                                    
        common stock, 0.001 par value...
      		76,000 75,000 74,000 74,000 74,000 73,000 73,000 73,000 73,000 72,000 72,000 72,000 72,000 71,000 71,000 71,000 71,000 71,000 71,000 70,000 70,000 69,000 69,000 69,000 69,000 68,000 59,000 59,000 59,000 58,000 58,000 58,000 58,000 49,000 49,000 48,000 42,000 42,000 42,000 38,000 38,000 38,000 38,000 37,000 37,000 37,000 35,000 34,000 32,000 31,000 31,000 4,000 
        additional paid-in capital
      		2,572,655,000 2,555,037,000 2,538,357,000 2,521,545,000 2,506,788,000 2,493,811,000 2,478,066,000 2,464,284,000 2,451,620,000 2,436,523,000 2,421,862,000 2,410,905,000 2,398,930,000 2,386,325,000 2,374,755,000 2,362,327,000 2,351,147,000 2,334,348,000 2,322,460,000 2,306,304,000 2,265,713,000 2,242,801,000 2,225,538,000 2,203,599,000 2,181,517,000 2,156,363,000 1,861,523,000 1,839,710,000 1,818,393,000 1,794,283,000 1,775,113,000 1,743,657,000 1,717,609,000 1,174,904,000 1,160,048,000 1,142,233,000 857,107,000 842,013,000 828,043,000 652,574,000 640,124,000 630,078,000 619,451,000 607,708,000 598,494,000 591,334,000 347,947,000 344,490,000 246,970,000 244,881,000 243,601,000 2,836,000 
        accumulated other comprehensive income
      		-314,000 2,193,000 2,051,000 655,000 365,000  3,420,000           -1,198,000 -198,000 -144,000 -3,000 105,000 663,000 1,636,000 74,000 202,000 464,000 490,000           29,000 297,000 89,000  225,000 222,000 191,000 -57,000 51,000 12,000 33,000 14,000 25,000  
        accumulated deficit
      		-660,816,000 -561,705,000 -453,666,000 -350,233,000 -238,213,000 -148,924,000 -52,401,000 -1,000,316,000 -904,198,000 -822,649,000 -726,709,000 -635,385,000 -551,579,000 -470,561,000 -507,087,000 -425,340,000 -333,534,000 -238,760,000 -144,133,000 -55,367,000  -1,843,475,000 -1,745,818,000 -1,646,839,000 -1,556,361,000 -1,516,105,000 -1,413,755,000 -1,307,582,000 -1,197,711,000 -1,104,633,000 -1,012,839,000 -918,175,000 -849,430,000 -798,061,000 -709,776,000 -632,639,000 -549,557,000 -483,151,000 -426,665,000 -363,831,000 -307,878,000 -284,680,000 -244,057,000 -203,802,000 -171,905,000 -166,948,000 -140,284,000 -143,988,000 -125,692,000 -113,444,000 -101,062,000 -89,885,000 
        treasury stock
      		-802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -802,486,000 -783,438,000 -529,047,000                                 
        total stockholders’ equity
      		1,109,115,000 1,193,114,000 1,284,330,000 1,369,555,000 1,466,528,000 1,540,956,000 1,626,672,000 660,510,000 743,922,000 811,019,000 886,843,000 964,236,000 1,036,526,000 1,100,814,000 1,050,170,000 1,124,070,000 1,207,453,000 1,291,975,000 1,394,762,000 1,721,816,000 2,296,630,000 399,500,000 480,452,000 558,465,000 625,299,000 640,528,000 448,291,000 532,677,000 620,257,000 687,537,000 760,213,000 823,142,000 865,594,000 375,503,000 449,806,000 508,992,000 307,380,000 358,591,000 401,449,000 289,078,000 332,373,000 345,118,000 375,657,000 404,165,000 426,817,000 424,366,000 207,749,000 200,548,000 121,343,000 131,482,000 142,595,000  
        total liabilities and stockholders’ equity
      		1,184,990,000 1,297,225,000 1,385,705,000 1,471,237,000 1,555,518,000 1,663,199,000 1,791,794,000 773,063,000 849,709,000 937,118,000 1,007,258,000 1,085,153,000 1,151,298,000 1,238,718,000 1,180,320,000 1,252,467,000 1,335,859,000 1,437,736,000 1,541,498,000 1,874,603,000 2,488,434,000 852,952,000 908,449,000 976,141,000 799,738,000 890,741,000 698,616,000 783,870,000 822,131,000 858,457,000 929,079,000 998,235,000 1,040,126,000 614,397,000 687,200,000 760,600,000 557,316,000 619,094,000 672,042,000 557,601,000 396,117,000 420,065,000 449,086,000 474,383,000 474,336,000 491,904,000 269,608,000 272,030,000 181,912,000    
        income taxes payable
      		    683,000 871,000 52,682,000                                           1,462,000 5,257,000 5,141,000 
        commitments and contingent liabilities
      		                                                    
        accumulated other comprehensive loss
      		     -1,518,000  -1,045,000 -1,087,000 -441,000 -5,896,000 -8,870,000 -8,411,000 -12,535,000 -15,083,000 -10,502,000 -7,745,000            -484,000 -2,171,000 -2,119,000 -2,398,000 -2,643,000 -1,389,000 -515,000 -650,000 -212,000 -313,000    -318,000          -5,000 
        other receivable
      		              3,774,000 2,704,000 5,365,000 4,378,000 6,990,000 8,131,000                                 
        financing lease assets
      		               64,000 95,000 183,000 300,000 871,000 502,000 590,000 677,000 793,000 881,000 993,000                           
        financing lease liabilities
      		              83,000 167,000 250,000 331,000 412,000 839,000 321,000 317,000 313,000 309,000 306,000 273,000                           
        financing lease liabilities, net of current portion
      		                276,000 276,000  167,000 248,000 331,000 412,000 491,000 571,000 673,000                           
        deferred revenue
      		                2,500,000                                 25,072,000 25,072,000 25,072,000 
        current assets of discontinued operations
      		                                                    
        non-current assets of discontinued operations
      		                                                    
        current liabilities of discontinued operations
      		                                                    
        non-current liabilities of discontinued operations
      		                                                    
        taxes payable
      		                  8,059,000 7,170,000 13,370,000                                
        retained earnings
      		                    30,850,000                                
        collaboration receivable – related party
      		                     2,123,000 2,334,000 2,537,000 2,577,000 1,539,000 1,838,000 2,524,000 2,319,000 2,462,000 3,395,000 19,326,000 3,512,000 2,448,000 3,489,000 4,842,000 11,265,000 4,886,000 8,182,000 7,853,000 6,814,000 8,225,000 9,078,000 10,474,000 7,017,000 6,492,000 18,759,000      
        collaboration receivable – other
      		                     1,948,000 1,992,000 1,827,000 2,033,000 1,928,000 869,000 2,222,000 1,640,000 670,000 440,000 440,000                     
        royalty receivable – related party
      		                       1,650,000 3,300,000 2,900,000 2,600,000 2,700,000 2,200,000 2,234,000 1,863,000 1,573,000 1,417,000 1,222,000 715,000                  
        deferred revenue – related party
      		                        4,748,000 10,933,000 16,873,000 18,454,000 22,167,000 32,710,000 42,141,000 41,132,000 39,212,000 37,842,000 35,867,000 37,069,000 37,690,000 35,913,000 36,415,000 31,469,000 16,523,000 19,665,000 22,650,000 22,608,000 6,886,000 35,686,000 18,847,000      
        deferred revenue, net of current portion – related party
      		                         50,580,000 49,797,000 51,616,000 54,961,000 59,809,000 66,294,000 72,408,000 81,831,000 125,798,000 134,202,000 141,957,000 150,596,000 154,297,000 173,941,000 183,540,000 1,949,000 4,699,000 6,240,000 9,389,000 133,000 2,725,000 26,352,000 26,697,000     
        liability related to the sale of future revenue, net of debt issuance costs
      		                     261,269,000 258,121,000 250,958,000                             
        other assets
      		                      1,350,000 1,575,000 1,800,000               1,382,000 838,000 611,000 678,000 660,000 640,000 590,000 454,000 455,000 467,000 4,000 11,000 1,624,000 
        deferred rent
      		                             766,000 686,000 625,000 550,000 301,000 3,586,000 3,529,000 3,473,000 3,412,000 3,356,000 2,933,000 2,539,000 2,479,000 2,150,000 2,092,000 1,245,000 310,000  142,000 133,000 123,000  104,000 
        deferred rent, net of current portion
      		                             17,608,000 17,826,000 17,815,000 18,002,000 18,155,000 15,080,000 16,003,000 16,911,000 17,773,000 18,649,000 17,719,000 16,740,000 17,360,000 17,433,000 15,631,000 11,007,000 3,724,000 423,000 145,000 186,000 220,000  288,000 
        tenant improvement and other receivables
      		                                 169,000 859,000 779,000 3,452,000 3,428,000 3,387,000 2,014,000 571,000 3,374,000 2,992,000 5,282,000 6,906,000        
        commitments and contingencies
      		                                                    
        refundable income taxes
      		                                             3,841,000 3,841,000 3,841,000 4,496,000    
        other current liabilities
      		                                            4,000 6,000 8,000 8,000 624,000  144,000  
        other receivables
      		                                             2,334,000       
        restricted cash
      		                                               571,000 571,000 571,000 571,000 571,000 
        unbilled collaboration receivable – related party
      		                                                    
        deferred revenue– related party
      		                                               33,644,000     
        unbilled collaboration receivable—related party
      		                                                2,619,000    
        deferred revenue—related party
      		                                                25,072,000    
        deferred revenue, net of current portion—related party
      		                                                26,299,000    
        unbilled collaboration receivable
      		                                                 476,000   
        deferred tax assets
      		                                                  1,246,000 1,247,000 
        liabilities, convertible preferred stock, and stockholders’ equity
      		                                                    
        restricted stock liability
      		                                                 9,000  38,000 
        deferred revenue, net of current portion
      		                                                 32,567,000 38,835,000 45,103,000 
        restricted stock liability, net of current portion
      		                                                 6,000  10,000 
        series a convertible preferred stock, 0.001 par value...
      		                                                   32,940,000 
        series b convertible preferred stock, 0.001 par value...
      		                                                   5,681,000 
        series c convertible preferred stock, 0.001 par value...
      		                                                   77,301,000 
        stockholders’ equity
      		                                                    
        total liabilities, convertible preferred stock, and stockholders’ equity
      		                                                 201,205,000 219,069,000  
        deferred tax assets, net of current portion
      		                                                  2,706,000 2,706,000 
        liabilities, convertible preferred stock, and stockholders’ deficit
      		                                                    
        stockholders’ deficit:
      		                                                    
        total stockholders’ deficit
      		                                                   -87,050,000 
        total liabilities, convertible preferred stock, and stockholders’ deficit
      		                                                   111,252,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 
                                                           
          operating activities
        		                                                   
          net loss
        		-99,111,000   -112,020,000 -89,289,000   -96,118,000 -81,549,000  -91,324,000 -83,806,000 -81,018,000         -97,657,000 -98,979,000 -90,478,000 -40,256,000 -102,350,000 -106,173,000 -109,871,000 -93,078,000 -91,794,000 -94,664,000 -68,745,000 -90,825,000 -88,285,000 -77,137,000 -83,082,000 -66,166,000 -56,486,000 -62,834,000 -55,953,000 -23,198,000 -40,622,000 -40,256,000 -31,897,000 -4,957,000 -26,664,000 3,704,000 -18,296,000 -12,248,000 -12,382,000 -11,177,000 
          adjustments to reconcile net loss from operations to net cash from operating activities:
        		                                                   
          depreciation and amortization
        		1,363,000 1,266,000 1,374,000 1,259,000 1,278,000 1,367,000 1,345,000 1,593,000 1,348,000 1,403,000 1,623,000 1,807,000 1,790,000 1,814,000 1,981,000 2,291,000 2,478,000 2,202,000 2,209,000 2,350,000 2,479,000 2,677,000                              
          stock-based compensation expense
        		15,541,000 14,124,000 12,377,000 14,692,000 11,359,000 10,903,000 11,145,000 11,565,000 9,234,000 13,814,000 9,076,000 11,737,000 10,139,000 11,465,000 11,156,000 11,165,000 15,510,000 11,621,000 12,148,000 14,885,000 14,854,000 16,595,000 18,407,000 20,430,000 19,690,000 17,130,000 18,588,000 18,547,000 18,108,000 18,187,000 24,193,000 16,455,000 14,522,000 12,681,000 12,207,000 12,187,000 10,734,000 9,840,000 12,143,000 10,996,000 9,107,000 9,353,000 9,373,000 8,177,000 5,060,000 4,728,000 2,892,000 2,381,000 1,505,000 1,165,000 1,112,000 
          net accretion of discount on marketable securities
        		-1,144,000 -1,753,000 -1,674,000 -2,420,000 -1,348,000 -5,616,000 -3,734,000 -2,609,000 -2,527,000                                           
          non-cash operating lease expense
        		3,258,000 3,196,000 3,135,000 3,076,000 3,018,000 2,962,000 2,909,000 2,856,000 2,803,000 2,753,000 2,704,000 2,655,000 2,608,000 2,563,000 2,513,000 2,483,000 2,436,000 2,408,000 2,369,000 2,343,000 2,417,000 2,291,000 2,256,000 2,232,000 2,203,000 2,191,000 2,133,000 2,123,000 2,085,000                       
          realized gain on investments
        		-28,000   0 -2,000 1,000 -15,000 -1,000 -152,000 0                                          
          changes in operating assets and liabilities:
        		                                                   
          accounts receivable
        		-5,555,000 -5,548,000 -43,000 -1,642,000 765,000 -991,000 644,000 -309,000 -643,000 -1,634,000 1,075,000 -473,000 428,000 -388,000 -220,000 -1,058,000 -540,000     -2,339,000 -6,966,000 -210,000 -2,861,000 -1,846,000 41,000 -2,792,000 721,000 -2,445,000                      
          inventory
        		-2,167,000 -886,000 -1,186,000 -1,243,000 -1,989,000 -1,187,000 -2,492,000 -867,000 -3,994,000 -1,802,000 -1,603,000 -4,297,000 -2,882,000 -3,316,000 -1,116,000 -1,575,000 -2,485,000     -3,327,000 -140,000 -1,453,000 -2,447,000 -1,482,000 -1,190,000 -2,331,000 -1,459,000 -6,000                      
          prepaid expenses and other current and non-current assets
        		-2,456,000 -945,000 1,519,000 -1,622,000 -2,124,000 -948,000 -5,349,000 4,577,000 -4,091,000 3,393,000 -1,663,000 2,451,000 -348,000 7,479,000 -4,099,000 -165,000 -3,391,000 -7,597,000 -10,795,000 -4,833,000 -3,621,000 5,434,000 -1,676,000 2,417,000 -6,774,000 -4,190,000 -1,035,000 -344,000 -2,173,000 -563,000 -702,000 512,000 1,901,000 -2,086,000 -2,027,000 1,008,000 -3,425,000 -231,000              
          accounts payable
        		-4,993,000 -1,145,000 1,807,000 3,905,000 -2,821,000 -756,000 7,089,000 -1,162,000 1,430,000 -3,532,000 1,636,000 2,959,000 -9,796,000 8,064,000 2,615,000 -2,236,000 -5,007,000 5,200,000 2,224,000 -2,620,000 -2,941,000 13,529,000 -116,000 -5,515,000 -2,009,000 1,067,000 4,523,000 3,065,000 -4,939,000 342,000 368,000 -1,729,000 -4,469,000 4,587,000 -4,188,000 5,924,000 -994,000 1,833,000 -2,087,000 4,048,000 -293,000 5,539,000 -114,000 1,455,000 -2,665,000 5,223,000 670,000 964,000 720,000 1,208,000 -907,000 
          accrued expenses and other current liabilities
        		-19,166,000  1,928,000 14,528,000 -26,100,000  -3,435,000 11,613,000 -18,038,000  1,301,000 6,730,000 -7,891,000  1,373,000 8,636,000 -12,220,000  -120,000 10,150,000 -12,697,000                               
          income taxes payable
        		 0 0 -683,000 -188,000 -51,811,000                                            -3,684,000 116,000 
          operating lease liabilities
        		-4,462,000 -4,308,000 -4,245,000 -4,180,000 -4,048,000 -3,846,000 -3,786,000 -3,727,000 -3,649,000 -3,502,000 -3,448,000 -3,392,000 -3,321,000 -3,182,000 -2,095,000 -3,146,000 -2,405,000 -2,212,000 -1,684,000 -2,127,000 -1,504,000 -2,015,000 -1,963,000 -1,920,000 -2,229,000 -2,671,000 -541,000 -1,520,000 -2,129,000                       
          net cash from operating activities
        		-118,920,000 -96,213,000 -88,151,000 -77,124,000 -111,489,000 -133,167,000 -84,218,000 -72,589,000 -99,867,000 -72,488,000 -61,643,000 -66,748,000 -95,183,000 -66,163,000 -71,351,000 -74,229,000 -97,735,000 9,141,000 -85,184,000 -117,294,000 -120,749,000 -49,397,000 -68,207,000 -67,797,000 -105,358,000 -93,611,000 -85,589,000 -88,151,000 -103,271,000 -74,187,000 -63,839,000 -67,395,000 -99,000,000 -74,454,000 -77,715,000 -58,989,000 -74,074,000 -51,223,000 -49,030,000 157,824,000 -19,009,000 -30,529,000 -24,815,000 3,980,000 -25,585,000 -7,775,000 -23,467,000 -1,071,000 -27,040,000 -13,617,000 -14,980,000 
          capital expenditures
        		-101,000 -1,120,000 -1,341,000 -875,000 -545,000 -967,000 -419,000 -158,000 -141,000 -193,000 -361,000 3,000  -113,000 -38,000 -1,926,000 -2,804,000 -3,310,000 452,000 -199,000 -1,006,000 -737,000 -8,640,000 -6,056,000 989,000 -3,745,000 -484,000 -1,463,000 -1,311,000 -448,000 -4,004,000 -601,000 -827,000 -495,000 -3,176,000 135,000 -80,000 -1,222,000 -4,289,000 -1,981,000 -1,926,000 -2,186,000 -3,750,000 -10,882,000 2,805,000 -1,489,000 -443,000 -87,000 0 -219,000 -99,000 
          free cash flows
        		-119,021,000 -97,333,000 -89,492,000 -77,999,000 -112,034,000 -134,134,000 -84,637,000 -72,747,000 -100,008,000 -72,681,000 -62,004,000 -66,745,000  -66,276,000 -71,389,000 -76,155,000 -100,539,000 5,831,000 -84,732,000 -117,493,000 -121,755,000 -50,134,000 -76,847,000 -73,853,000 -104,369,000 -97,356,000 -86,073,000 -89,614,000 -104,582,000 -74,635,000 -67,843,000 -67,996,000 -99,827,000 -74,949,000 -80,891,000 -58,854,000 -74,154,000 -52,445,000 -53,319,000 155,843,000 -20,935,000 -32,715,000 -28,565,000 -6,902,000 -22,780,000 -9,264,000 -23,910,000 -1,158,000 -27,040,000 -13,836,000 -15,079,000 
          investing activities
        		                                                   
          purchases of marketable securities
        		-148,182,000 -161,078,000 -174,981,000 -130,797,000 -174,903,000 -198,326,000 -995,503,000 -104,545,000 -244,059,000 -90,440,000 -95,004,000 -104,135,000 -128,351,000 -248,563,000 -174,471,000 -251,831,000 -355,916,000 -426,810,000 -452,515,000 -437,033,000 -61,863,000 -126,406,000 -241,023,000 -134,690,000 -54,911,000 -293,744,000 -50,591,000 -66,810,000 -77,421,000 -177,952,000 -162,704,000 -261,693,000 -330,971,000 -84,177,000 -135,969,000 -441,816,000 -26,740,000 -138,480,000 -141,298,000 -15,126,000 -211,163,000 -134,520,000 -112,452,000 -70,679,000 -35,526,000 -621,836,000 -89,045,000 -91,526,000 -34,812,000 -26,551,000 -96,303,000 
          proceeds from maturities and sales of marketable securities
        		290,263,000 252,274,000 272,091,000 220,638,000 288,256,000 150,135,000 157,579,000 141,947,000 368,722,000 186,187,000 151,039,000 151,257,000 186,196,000 198,879,000 278,579,000 336,570,000 332,147,000 336,893,000 219,762,000 139,133,000 134,016,000 198,819,000 119,983,000 161,382,000 167,501,000 115,795,000 133,010,000 132,561,000 210,811,000 166,200,000 168,615,000 166,795,000 164,871,000 127,305,000 204,405,000 167,126,000 136,585,000 62,184,000 81,980,000 53,600,000 198,868,000 157,664,000 145,908,000 113,767,000 84,311,000 336,023,000 74,004,000 72,941,000 22,560,000 6,360,000 15,680,000 
          purchases of property and equipment
        		-769,000 -1,120,000 -1,555,000 -875,000 -766,000 -967,000 -419,000 -158,000 -141,000 -234,000 -369,000 3,000 -399,000 -113,000 -38,000 -1,926,000 -2,804,000 -4,502,000 22,000 -249,000 -1,012,000 -1,017,000 -5,204,000 -4,233,000 -4,455,000 -6,824,000 -2,038,000 -1,271,000 -2,038,000 -1,053,000 -3,140,000 -1,361,000 -1,432,000 -1,280,000 -2,019,000 -1,035,000 -293,000 -1,222,000 -3,426,000 -2,734,000 -2,533,000 -2,186,000 -3,299,000 -10,882,000 -3,797,000 -1,489,000 -628,000 -86,000 -13,000 -219,000 -99,000 
          net cash from investing activities
        		141,312,000 90,076,000 95,555,000 78,966,000 112,587,000 -49,158,000 250,793,000 37,244,000 124,562,000 95,513,000 39,341,000 47,125,000 57,596,000 82,951,000 104,070,000 82,813,000 -26,573,000 -1,897,355,000 -232,731,000 -298,149,000 1,874,077,000 71,396,000 -126,244,000 22,459,000 108,135,000 -184,773,000 80,381,000 64,480,000 131,352,000 -12,805,000 2,771,000 -96,259,000 -167,532,000 41,848,000 66,417,000 -275,725,000 109,552,000 -77,518,000 -62,744,000 35,740,000 -14,828,000 20,958,000 30,157,000 32,206,000 44,988,000 -287,302,000 -15,098,000 -18,671,000 -12,265,000 -20,410,000 -80,722,000 
          financing activities
        		                                                   
          net proceeds from stock option exercises and employee stock purchase plan
        		2,078,000 2,557,000 4,435,000 65,000 1,619,000 4,842,000 2,637,000 1,099,000 5,864,000 847,000 1,882,000 237,000 2,467,000 105,000 1,271,000 16,000 1,289,000 267,000 4,009,000 25,673,000 7,347,000 668,000 3,532,000 1,652,000 5,465,000 518,000 3,337,000 3,808,000 4,860,000 1,016,000 7,223,000 9,711,000 12,259,000  5,515,000 2,699,000 4,146,000  1,202,000 1,449,000 1,108,000  2,173,000 1,091,000 2,029,000       
          net cash from financing activities
        		2,078,000 2,557,000 4,435,000 65,000 1,619,000 4,842,000 2,637,000 1,099,000 5,864,000 847,000 1,882,000 237,000 2,467,000 22,000 1,187,000 -67,000 1,208,000 -18,586,000 -250,985,000 -503,458,000 7,261,000 582,000 3,448,000 252,103,000 5,385,000 277,606,000 3,337,000 3,808,000 4,860,000 1,016,000 7,223,000 9,508,000 528,277,000 2,589,000 5,322,000 273,153,000 4,046,000 3,993,000 163,228,000 1,449,000 1,108,000 1,287,000 2,173,000 1,091,000 1,822,000 239,059,000 367,000 95,152,000 582,000 -424,000 124,232,000 
          net change in cash and cash equivalents
        		24,470,000 -3,580,000 11,839,000 1,907,000 2,717,000 -177,483,000 169,212,000 -34,246,000 30,559,000 23,872,000 -20,420,000 -19,386,000 -35,120,000 16,810,000 33,906,000 8,517,000 -123,100,000 -197,098,000 -568,900,000 -918,901,000 1,760,589,000 22,581,000 -191,003,000 206,765,000 8,162,000 -778,000 -1,871,000 -19,863,000 32,941,000 -85,976,000 -53,845,000 -154,146,000 261,745,000 -30,017,000 -5,976,000 -61,561,000 39,524,000               
          cash and cash equivalents at beginning of the period
        		89,130,000 0 0 0 76,247,000 0 0 0 88,205,000 0 0 0 139,259,000 0 0 0 203,126,000 0 0 0 127,436,000 0 0 0 80,931,000 0 0 0 70,502,000 0 0 0 102,724,000 0 0 0 160,754,000 0 0 0 71,764,000 0 0 0 14,031,000 0 0 0 71,560,000 0 0 
          cash and cash equivalents at end of the period
        		113,600,000 -3,580,000 11,839,000 1,907,000 78,964,000 -177,483,000 169,212,000 -34,246,000 118,764,000 23,872,000 -20,420,000 -19,386,000 104,139,000 16,810,000 33,906,000 8,517,000 80,026,000 -197,098,000 -568,900,000 -918,901,000 1,888,025,000 22,581,000 -191,003,000 206,765,000 89,093,000 -778,000 -1,871,000 -19,863,000 103,443,000 -85,976,000 -53,845,000 -154,146,000 364,469,000 -30,017,000 -5,976,000 -61,561,000 200,278,000 -124,748,000 51,454,000 195,013,000 39,035,000 -8,284,000 7,515,000 37,277,000 35,256,000 -56,018,000 -38,198,000 75,410,000 32,837,000 -34,451,000 28,530,000 
          supplemental disclosure of non-cash investing and financing transactions
        		                                                   
          additions to property and equipment in accounts payable
        		668,000  214,000                                                 
          exchanges of marketable securities
        		2,229,000                                                   
          net cash taxes paid
        		4,000 -940,000 65,000       -17,000                                          
          net income
        		 -108,039,000    -96,523,000        36,526,000 -81,747,000 -91,806,000 -94,774,000 -94,627,000 -88,766,000 -86,217,000 1,874,325,000                               
          adjustments to reconcile net income to net cash from operating activities:
        		                                                   
          gain on sale of contingent payments
        		     0                                              
          loss on disposal of property and equipment
        		 -299,000 299,000   0    275,000 428,000   -77,000 19,000   3,000 -3,000       586,000    40,000 0   0 0                 
          expense associated with license agreement
        		 0 0       0                                          
          milestone payment from gain on sale of oncology business
        		     0                                              
          accrued expenses
        		                     10,598,000 8,757,000 6,372,000 -14,967,000 2,631,000 -2,469,000 12,168,000 -5,097,000 17,160,000 -696,000 9,303,000 -17,144,000 2,764,000 1,150,000                 
          other liabilities
        		                                                   
          proceeds from sale of contingent payments
        		     0                                              
          proceeds from milestone payment from gain on sale of oncology business
        		     0                                              
          payments associated with license agreement
        		 0 0       0                                          
          proceeds from sale of equipment
        		     0 0 0 40,000 0 1,175,000 0 150,000                                       
          supplemental disclosure of non-cash investing and financing transactions:
        		                                                   
          additions to property and equipment in accounts payable and accrued expenses
        		    221,000     41,000 8,000       1,192,000 430,000 50,000 6,000 280,000 -3,436,000 -1,823,000 5,444,000 3,079,000 1,554,000 -192,000 727,000 605,000 -864,000 760,000 605,000 785,000 -1,157,000 1,170,000 213,000      -451,000         
          other non-current liabilities
        		  -11,000        0 -157,000 -1,966,000  0                                     
          gain on disposal of property and equipment
        		       0 -39,000    -150,000                                       
          net cash taxes (returned) paid
        		    188,000   -78,000 -525,000                                           
          other receivables
        		             -157,000 -1,070,000 2,661,000 -987,000 2,612,000 1,141,000                       -381,000 2,289,000 1,625,000 -4,573,000       
          payments on financing lease obligations
        		             -83,000 -84,000 -83,000 -81,000 195,000 -603,000 -84,000 -86,000 -86,000 -84,000 -86,000 -80,000                           
          less: net income from discontinued operations
        		                 3,957,000 -4,507,000 -3,427,000 1,965,202,000                               
          net loss from continuing operations
        		             36,526,000 -81,747,000 -91,806,000 -94,774,000 -98,584,000 -84,259,000 -82,790,000 -90,877,000                               
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                   
          net (accretion of discount) amortization of premium on marketable securities
        		         -393,000 1,080,000                                         
          net cash from operating activities - continuing operations
        		              -71,351,000 -74,229,000 -97,735,000  -74,866,000 -69,003,000 -90,226,000                               
          net cash from operating activities - discontinued operations
        		                 -4,102,000 -10,318,000 -48,291,000 -30,523,000                               
          net cash from investing activities - continuing operations
        		              104,070,000 82,813,000 -26,573,000  -232,731,000 -298,149,000 71,141,000                               
          net cash from investing activities - discontinued operations
        		                 0 0 0 1,802,936,000                               
          purchase of treasury stock
        		                 -19,048,000 -254,391,000                                 
          financing lease liabilities arising from obtaining financing lease assets
        		                 0 0                                 
          cash taxes paid
        		                                                   
          net amortization of premium (accretion of discount) on marketable securities
        		            -2,776,000  -661,000 232,000 1,150,000 1,623,000 1,904,000 1,758,000 1,664,000                               
          deferred revenue
        		                2,500,000                                 -6,268,000 -6,268,000 
          net cash from financing activities - discontinued operations
        		                                                   
          adjustments to reconcile net loss from continuing operations to net cash from operating activities:
        		                                                   
          net cash from financing activities - continuing operations
        		              1,187,000 -67,000 1,208,000  -250,985,000 -503,458,000 7,261,000                               
          proceeds from public offering of common stock, net of reimbursements
        		                                                   
          operating lease liabilities arising from obtaining operating lease assets
        		                         0 -534,000                         
          non-cash interest expense associated with the sale of future revenue
        		                     6,014,000 9,767,000                             
          non-cash royalty revenue
        		                     -2,953,000 -2,691,000                             
          collaboration receivable – related party
        		                     211,000 203,000 40,000 -1,038,000 299,000 686,000 -205,000 143,000 933,000 15,931,000 -15,814,000 -1,064,000 1,041,000 1,353,000 6,423,000 -6,379,000 3,296,000 -329,000 -1,039,000 1,411,000 852,000 1,397,000 -3,458,000 -524,000 12,267,000      
          collaboration receivable – other
        		                     44,000 -165,000 206,000 -105,000 -1,059,000 1,353,000 -582,000 -970,000 -230,000 0                     
          royalty receivable – related party
        		                     0 1,650,000 1,650,000 -400,000 -300,000 100,000 -500,000 34,000 -371,000 -290,000 -156,000 -195,000 -507,000                  
          deferred revenue – related party
        		                     0 0 -4,748,000 -56,765,000 -5,157,000 -3,400,000 -7,058,000 -15,391,000 -15,916,000 -5,105,000 -7,503,000 -3,141,000 -6,429,000 -8,957,000 -9,260,000 -1,924,000 -20,146,000 -4,653,000 196,537,000 -5,892,000 -4,525,000 -3,108,000 24,979,000 -31,393,000 -6,789,000 -15,141,000     
          deferred rent
        		                             -138,000 72,000 -112,000 96,000 -210,000 -866,000 -852,000 -801,000 -820,000 1,353,000 1,373,000 -560,000 256,000 1,860,000 5,471,000 8,218,000 3,611,000 135,000 -31,000 -24,000   
          reimbursement (payment) of public offering costs
        		                                                   
          proceeds from the sale of future revenue, net of issuance costs
        		                     0 0                             
          proceeds from stock option exercises in other current assets
        		                           -1,037,000 1,149,000 -32,000   73,000    6,000   6,000 17,000 -14,000 197,000 -57,000 60,000 -164,000      
          net accretion of premium and discounts on investments
        		                      1,048,000 347,000 126,000  -753,000                         
          depreciation
        		                       2,432,000 2,474,000  2,082,000 2,037,000 2,005,000 1,911,000 1,797,000 1,739,000 1,725,000 1,654,000 1,614,000 1,573,000 1,591,000 1,722,000 1,436,000 1,304,000 1,246,000 1,145,000 1,047,000 780,000 370,000 362,000 346,000 327,000 332,000 340,000 377,000 
          payment of public offering costs, net of reimbursements
        		                              0 -203,000 -188,000                   
          proceeds from public offering of common stock, net of commissions
        		                              0 0 516,206,000 0 0   0              
          net amortization of premium and discounts on investments
        		                            -1,131,000  -1,249,000 -885,000 -406,000  -69,000 -69,000 163,000  204,000 204,000 126,000    172,000       
          public offering costs in other current assets, net of amounts in accounts payable and accrued expenses
        		                                     106,000              
          (payment) reimbursement of public offering costs
        		                                                   
          public offering costs in other receivables, net of amounts in accounts payable and accrued expenses
        		                                  193,000                 
          tenant improvement and other receivables
        		                                 372,000 -80,000 2,662,000 -24,000 4,000 -1,089,000 -1,443,000 2,803,000           
          public offering costs in other current assets
        		                                    329,000               
          public offering costs in accounts payable and accrued expenses
        		                                158,000                   
          refundable income taxes and income taxes payable
        		                                         0 0 0 3,841,000 0 0 655,000 -5,958,000   
          net proceeds from stock option exercises and employee stock purchase plan, and vesting of restricted stock units
        		                                                   
          vesting of restricted stock
        		                                         12,000 -2,000 -6,000 2,000 16,000 -1,000 -9,000 3,000   
          proceeds from stock option exercises in other receivables
        		                                  92,000                 
          adjustments to reconcile net loss cash from operating activities:
        		                                                   
          reimbursement of public offering costs, net of payments
        		                                                   
          loss on disposal of fixed assets
        		                                    40,000               
          accrued expenses and other liabilities
        		                                    -6,889,000  8,161,000 2,069,000 -2,902,000 -836,000 5,027,000 -4,132,000 1,574,000 1,817,000 4,544,000 1,064,000 -2,194,000 2,398,000 635,000 
          payment of public offering costs
        		                                    -100,000 -106,000       -207,000       
          net loss on disposal of fixed assets
        		                                                   
          net amortization of premiums and discounts on marketable securities
        		                                                   
          release of restricted cash
        		                                             0      
          net proceeds from stock option exercises and employee stock purchase plan and vesting of restricted stock units
        		                                                   
          net increase in cash and cash equivalents
        		                                     -124,748,000 51,454,000 195,013,000 -32,729,000 -8,284,000 7,515,000 37,277,000 21,225,000  -38,198,000   -34,451,000  
          supplemental cash flow information
        		                                                   
          cash paid for income taxes
        		                                             22,000 0 0 5,958,000   
          additions to property, plant and equipment included in accounts payable and accrued expenses
        		                                                   
          additions to property, plant and equipment in accounts payable and accrued expenses
        		                                      -863,000 753,000 607,000    6,602,000       
          prepaid expenses and other assets
        		                                       -272,000 -857,000 -1,451,000 -2,442,000 833,000 -708,000 -122,000 -1,965,000 139,000 -930,000 122,000 1,006,000 
          deferred taxes
        		                                                   
          net amortization of premiums and discounts on investments
        		                                                   
          proceeds from private placement
        		                                                   
          net proceeds from stock option exercises and issuance of common stock
        		                                              380,000 454,000 582,000   
          conversion of convertible preferred stock upon initial public offering
        		                                                   
          net amortization of premium on investments
        		                                          112,000         
          net proceeds from public offering of common stock, (payment of) commissions and offering costs
        		                                          0         
          net proceeds from stock option exercises and issuance of common and restricted common stock
        		                                                   
          net decrease in cash and cash equivalents
        		                                                -38,723,000   
          proceeds from public offering of common stock, net of commissions and offering costs
        		                                              -13,000     
          additions to property, plant and equipment included in accounts payable
        		                                              185,000 -1,000 13,000   
          conversion of convertible preferred stock into common stock
        		                                                   
          public offering costs included in accounts payable
        		                                                   
          net amortization of premium (discount) on investments
        		                                               137,000 168,000   
          unbilled collaboration receivable – related party
        		                                                   
          unbilled collaboration receivable—related party
        		                                                -2,143,000   
          deferred revenue—related party
        		                                                -6,268,000   
          accrual of public offering costs
        		                                                65,000   
          unbilled collaboration receivable
        		                                                   
          proceeds from initial public offering, net of commissions
        		                                                   
          payment of initial public offering costs
        		                                                   
          net proceeds from issuance of series c convertible preferred stock
        		                                                   
          amortization of premium (discount) on investments
        		                                                   
          proceeds from initial public offering and private placement of common stock
        		                                                   
          net proceeds from stock option exercises
        		                                                   
          non-cash financing activities
        		                                                   
          initial public offering costs incurred but unpaid at period end
        		                                                   
          amortization of (discount) premium on investments